268 results about "Drug" patented technology

The present invention pertains to a pharmaceutical dosage form comprising an opioid agonist and one or more opioid antagonists contained in a matrix separate from the opioid agonist. The separate matrix for the opioid antagonist allows independent release rates to be achieved for the opioid and opioid antagonist(s). The antagonist(s) can be released slowly or fully contained when the tablet is taken orally. Crushing the tablet allows full release of the antagonist(s), deterring abuse. The abuse deterring antagonist(s) may be an opioid antagonist, an irritant, another appropriate antagonist(s), or a combination thereof. The invention also allows variable release of the opioid and antagonist(s).

A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Disclosed herein are novel buprenorphine monocarboxylic ester derivatives and dibuprenorphine dicarboxylic ester derivatives which exert a longer analgesic effect as compared to buprenorphine hydrochloride. Also disclosed are the processes for synthesizing the novel ester derivatives of buprenorphine, and long-acting analgesic pharmaceutical compositions containing a compound selected from buprenorphine base and the novel ester derivatives of buprenorphine.

The invention provides a CRISPR-Cas9 system for preventing and/or treating HIV, as well as a preparation method and application thereof. The CRISPR-Cas9 system comprises sgRNA of a specific genetic locus on a specific target HIV genome, wherein the specific genetic locus on the HIV genome is selected from Gag, Env, Pol, Tat, Nef, Vif, Vpr, Vpu, 5'LTR, 3'LTR and Rev. The preparation method of the CRISPR-Cas9 system comprises the step of preparing an sgRNA fragment by means of PCR amplification. The invention further provides application of the CRISPR-Cas9 system in preparation of medicines for treating and/or preventing HIV infection. By adopting an efficient gene delivery system, the CRISPR-Cas9 system is delivered into HIV infected cells to efficiently inhibit generation of HIV, the inhibition rate is 96 percent, and the effect equivalent to that of peptide anti-HIV medicines can be achieved.

Pharmaceutical composition comprising micro particles having an average diameter ranging from 40 to 150 nm, consisting of one or more lipids, a drug and, optionally, a steric stabilizer, suitable to the transmucosal passage and to the overcoming of the blood-brain barrier and the blood-cerebrospinal fluid barrier, said micro particles being obtained dispersing in an aqueous medium cooled to 2-4° C. an oil/water or a water/oil/water micro emulsion comprising said constituents.

The invention discloses a novel andrographolide derivative and analogue as well as a preparation method of the novel andrographolide derivative and analogue and an application to the treatment, the prevention and the relief on human viruses and neoplastic diseases. The invention also relates to a medicine composition of the compound and an application as antivirus and anticancer disease medicine. Through chemical synthesis and preparation, semi-synthesis multi-series andrographolide analogues can be obtained.

The invention provides a compound for targeted ubiquitinated degradation of Smad3. The compound for targeted ubiquitinated degradation of Smad3 is formed by connecting a compound shown in a formula (I) and an ubiquitin ligase E3 identifying ligand shown in a formula (II) through a Linker shown in a formula (III) for connecting the two. The invention constructs a compound which can be specifically combined with Smad3 to degrade Smad3 proteins in a targeted manner through ubiquitination by jointly applying computer virtual screening and a technology of target ubiquitinated degradation of proteins, and the compound is verified to be capable of degrading Smad3 in a targeted ubiquitinated manner. As Smad3 is the major known fibrosis-inducing signaling protein, the Protac theoretically has an anti-fibrosis effect. Moreover, the molecular weight of the compound is small, so that the Protac can get into or out of cells freely, and therefore, the compound is likely to become a novel drug for treating fibrosis. The compound not only has scientific value, but also has important social value.

Methods are provided for preparing spray-dried, drug-containing particles comprising the steps of selecting (i) a drug and an optional excipient, wherein the combination of the drug and optional excipient has an effective pI, and (ii) an aqueous solution having a pH that is different from the effective pI; (b) combining the solution and the drug and optional excipient, wherein an absolute net charge is associated with the drug and optional excipient as a result of an absolute difference between the pH and effective pI; and (c) spray drying the solution to form the spray-dried, drug-containing particles. Particles and compositions comprising the prepared particles as well as methods of use are also provided.

This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer.

Some embodiments of a medication delivery system provides for the recommendation or delivery of an amount of medication to a patient based on physiological parameter information and a set or rules. Some embodiments provide for systems and methods of medication delivery based on physiological parameters of, a patient, such as blood glucose level, blood pressure, and the like.

A Chinese medicine in the form of pill, capsule, or decoction for treating liver cancer, lung cancer, blood cancer, stomach cancer and cardia cancer is prepared from Chinese-medicinal materials including green vitriol, toad, telini fly, carmbola root, etc.

The present invention is directed to a hard capsule filled with a solution containing an active ingredient, characterized in that the solution contains an inorganic chloride and has a water content (w) of 10<w≦80% and a water activity (a) of 0.50≦a≦0.90, and that the capsule is made of a base material containing a cellulose derivative. According to the present invention, a solution having high water content can be encapsulated, with its solution form being maintained. Thus, the present invention enables provision of a product which does not impair properties and stability of a drug or a similar substance, and does not impair sensation upon intake or eating sensation.

The invention discloses an intelligent pushing type drug discharging device, a drug dispensing control system and a drug managing and dispensing method. The intelligent pushing type drug discharging device is used for the intelligent drug dispensing control system and comprises a drug groove used for containing drug and a pushing device used for pushing the drug out of the drug groove. When drug discharging is needed, the pushing device pushes the drug towards the direction of a drug discharging outlet, and the moving length of the pushing device is equal to the length occupied by the drug to be discharged in the drug groove. When drug discharging is not needed, the pushing device does not form pushing force large enough to enable the drug to be pushed out of the drug groove. The intelligent pushing type drug discharging device can be placed at a small angle even zero angle, and is smaller in occupied space and capable of greatly improving the utility rate of space. According to the intelligent pushing type drug discharging device, the foundation of drug discharging counting is reliable, drug stock information can be updated in real time, drug validity date management can be conducted in real time, and maintaining cost is low. Preferably, the pushing device comprises a motor and a pushing component, the middle of the drug groove is hollow to form a channel, and the motor drives a pushing block on the pushing component to make linear reciprocating motion in the channel.

We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.

The invention relates to a method of treatment of resistance to platelet inhibitors, i.e. a method to overcome resistance of treatment with platelet inhibitors, said method comprising administering a therapeutically effective amount of dipyridamole in combination with a platelet inhibitor and, optionally, in combination with a third antithrombotic component such as direct thrombin inhibitors, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, heparin, low molecular weight heparin, argatroban, bivalrudin, hirulog or polyglycans to a patient in need thereof. The invention further relates to the use of dipyridamole for the manufacture of a pharmaceutical composition for treatment of resistance to platelet inhibitors. The invention also relates to a method to diagnose resistance to treatment with platelet inhibitors, said method comprising measurement of the density of binding of Annexin V on platelets.

The computerized method, software, and product of this invention implements a process for computationally designing proteins and/or associated molecular targets with desired quantitative stability/flexibility relationships (QSFR). QSFR is an innovative, high dimensional metric calculated using an improved Distance Constraint Model (DCM). This invention includes three distinct aspects: (i.) utilizing QSFR in computational molecular design of protein sequences, or variations of molecular structures, to have specific stability and flexibility relationships deemed important for biochemical function for specified thermodynamic and solvent conditions; (ii.) utilizing QSFR to optimize thermodynamic and/or solvent conditions necessary for a specified molecular system to exhibit protein function characteristics, such as improved catalytic efficiency; and (iii.) utilizing QSFR to computationally screen or design small molecules and/or design its putative receptor so as to exhibit a desired affect on protein function.

This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as 1-hexadecyl-2-(4′-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.

A helicidum analog with high selective suppression to acetylcholinesterase and its application in preparing the medicines for preventing and treating senile dementia are disclosed.

The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-α levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell disease. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases. The invention still discloses a new method for obtaining a specific sulphonamide derivative which can be used in the preparation of a drug for the treatment of diseases which require reducing the levels of the TNF-α factor and an exogenous source of nitric oxide.

The invention relates to a drug use warning information processing method. The method is characterized by comprising the steps of 1, receiving drug use medical order information generated by a first terminal; 2, extracting drug use information and disease condition information from the drug use medical order information; 3, querying a reasonable drug use rule library by utilizing the drug use information and the disease condition information, and when the drug use information does not conform to the reasonable drug use rule library, executing the step 4; and 4, generating a drug use unreasonable rule data set according to the reasonable drug use rule library, wherein the drug use unreasonable rule data set contains a drug use unreasonableness value; and 5, generating drug use warning information, wherein the drug use unreasonableness value is marked in the drug use warning information. According to the drug use warning information processing method provided by the invention, the unreasonable drug use situation can be avoided, so that the drug use safety of patients is improved.

The invention provides a medicine composition with a skin whitening effect as well as a preparation method and application thereof. The medicine composition with the skin whitening effect is prepared from the following raw materials in parts by weight: 1-60 parts of pyracantha fortuneana fruit, 1-60 parts of liquorice, 1-60 parts of mulberry,1-60 parts of angelica and 1-60 parts of saxifrage. The medicine composition has the obvious skin whitening effect and no irritation and sensitization to skin.

The invention discloses an external-use medicine for treating neck, shoulder, waist and leg diseases and osteoproliferation, and a preparation method of the medicine. The external-use medicine comprises active ingredients in parts by weight as shown in the description. The preparation method of the external-use medicine comprises the steps of wine soaking, drying, crushing, stirring, packaging and the like. The external-use medicine is completely prepared from traditional Chinese medicines and has the effects of warming channel, activating blood circulation, expelling wind, removing dampness, relieving swelling and pain, invigorating qi and blood, promoting blood circulation to remove blood stasis, tonifying kidney and strengthening du meridian. The external-use medicine has the advantages of good treatment effect, fast curative effect, very low toxicity, convenience in use and no limitation for treatment of the neck, shoulder, waist and leg diseases and the osteoproliferation. The preparation method is simple. The external-use medicine can be prepared into medicine packages which can be applied to home health care and medical treatment and are easy to carry.